366 related articles for article (PubMed ID: 23775433)
1. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Ito K; Elkin E; Blinder V; Keating N; Choudhry N
Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
[TBL] [Abstract][Full Text] [Related]
4. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Marchetti M; Caruggi M; Colombo G
Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
7. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
Choudhry NK; Patrick AR; Antman EM; Avorn J; Shrank WH
Circulation; 2008 Mar; 117(10):1261-8. PubMed ID: 18285564
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of extended adjuvant endocrine therapy in the treatment of post-menopausal women with hormone receptor positive breast cancer.
Erman A; Nugent A; Amir E; Coyte PC
Breast Cancer Res Treat; 2014 Jun; 145(2):267-79. PubMed ID: 24771048
[TBL] [Abstract][Full Text] [Related]
11. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Risebrough NA; Verma S; Trudeau M; Mittmann N
Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.
Thompson D; Taylor DC; Montoya EL; Winer EP; Jones SE; Weinstein MC
Value Health; 2007; 10(5):367-76. PubMed ID: 17888101
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer.
Lidgren M; Wilking N; Jönsson B; Rehnberg C
Acta Oncol; 2008; 47(6):1018-28. PubMed ID: 18607881
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
19. Long-term cost-effectiveness of providing full coverage for preventive medications after myocardial infarction.
Ito K; Avorn J; Shrank WH; Toscano M; Spettel C; Brennan T; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2015 May; 8(3):252-9. PubMed ID: 25944633
[TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.
Blank PR; Schwenkglenks M; Moch H; Szucs TD
Breast Cancer Res Treat; 2010 Nov; 124(2):497-507. PubMed ID: 20364309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
